Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
|Slideshows|May 31, 2018
New FDA Warning
Author(s)James Phelps, MD
A rare but serious reaction to this treatment can have immunological consequences. As with all medications, however, the latest alert does not change how psychiatrists manage the risks.
Advertisement
Advertisement
Related to this article
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
What Clinicians Need to Know About Postpartum Psychosis
2
Brain Trust: Therapeutic Drug Monitoring and Adherence in Schizophrenia, With Jonathan M. Meyer, MD
3
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
4
AI as a Task-Replacing Tool for Psychiatric Care: A Conversation With Christoph Correll, MD
5